dm+d

Unassigned

New Medicines

Mild-moderate Alzheimer's disease

Information

New molecular entity
Cassava Sciences
Cassava Sciences

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials

Category

First-in-class. PTI-125 binds to Filamin A (misfolded protein) and restores its normal shape and function. Taken twice daily.
Dementia affects 5.4% of the population over the age of 65, prevalence increases with age. Alzheimers disease is the most common form, about 50% of cases. It is estimated to affect about 496,000 people in the UK [2].
Mild-moderate Alzheimer's disease
Oral